All Stories

  1. Dietary burden of phosphorus and aluminum concentrations of ready-to-eat wheat flour tortillas exceed that of corn tortillas: Implications for patients with renal or cardiovascular disease
  2. Macrophage Polarization Status Impacts Nanoceria Cellular Distribution but Not Its Biotransformation or Ferritin Effects
  3. Carboxylic acids and light interact to affect nanoceria stability and dissolution in acidic aqueous environments
  4. Cerium dioxide, a Jekyll and Hyde nanomaterial, can increase basal and decrease elevated inflammation and oxidative stress
  5. Laser irradiation as a novel alternative to detach intact particulate matter collected on air filters
  6. Direct nose to the brain nanomedicine delivery presents a formidable challenge
  7. The preparation temperature influences the physicochemical nature and activity of nanoceria
  8. Correction to Some Statements about Aluminum in Sulaiman et al.
  9. Nanoceria distribution and effects are mouse-strain dependent
  10. Tissue Specific Fate of Nanomaterials by Advanced Analytical Imaging Techniques - A Review
  11. Nanoparticle brain delivery: a guide to verification methods
  12. Carboxylic acids accelerate acidic environment-mediated nanoceria dissolution
  13. Surface-controlled dissolution rates: a case study of nanoceria in carboxylic acid solutions
  14. Methods to Quantify Nanomaterial Association with, and Distribution Across, the Blood–Brain Barrier In Vivo
  15. Morphometric characteristics and time to hatch as efficacious indicators for potential nanotoxicity assay in zebrafish
  16. Physiologically based pharmacokinetic modeling of nanoceria systemic distribution in rats suggests dose- and route-dependent biokinetics
  17. Challenges in characterizing the environmental fate and effects of carbon nanotubes and inorganic nanomaterials in aquatic systems
  18. Analytical High-resolution Electron Microscopy Reveals Organ-specific Nanoceria Bioprocessing
  19. Toxic and Essential Trace Element Content of Commonly Administered Pediatric Oral Medications
  20. Biokinetics of nanomaterials: The role of biopersistence
  21. Aluminum and Phthalates in Calcium Gluconate
  22. Aluminum☆
  23. From Dose to Response: In Vivo Nanoparticle Processing and Potential Toxicity
  24. Physicochemical properties of engineered nanomaterials that influence their nervous system distribution and effects
  25. Aluminum: The Toxicology of
  26. Silver nanoparticles induce tight junction disruption and astrocyte neurotoxicity in a rat blood–brain barrier primary triple coculture model
  27. RNA nanoparticle as a vector for targeted siRNA delivery into glioblastoma mouse model
  28. Alternating Magnetic Field-Induced Hyperthermia Increases Iron Oxide Nanoparticle Cell Association/Uptake and Flux in Blood–Brain Barrier Models
  29. Introduction to the themed collection on nanoceria research
  30. Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts
  31. Applying accelerator mass spectrometry for low-level detection of complex engineered nanoparticles in biological media
  32. In Vivo Processing of Ceria Nanoparticles inside Liver: Impact on Free-Radical Scavenging Activity and Oxidative Stress
  33. Nanoceria exposure, uptake, disposition, persistence, and resultant adverse effects
  34. Nanoceria biodistribution and retention in the rat after its intravenous administration are not greatly influenced by dosing schedule, dose, or particle shape
  35. Aluminum
  36. Rat hippocampal responses up to 90 days after a single nanoceria dose extends a hierarchical oxidative stress model for nanoparticle toxicity
  37. Binding, Transcytosis and Biodistribution of Anti-PECAM-1 Iron Oxide Nanoparticles for Brain-Targeted Delivery
  38. Persistent Hepatic Structural Alterations Following Nanoceria Vascular Infusion in the Rat
  39. Assessing nanoparticle risk poses prodigious challenges
  40. Metal-based nanoparticle interactions with the nervous system: the challenge of brain entry and the risk of retention in the organism
  41. Biodistribution and biopersistence of ceria engineered nanomaterials: size dependence
  42. Aluminum
  43. Block Copolymer Cross-Linked Nanoassemblies Improve Particle Stability and Biocompatibility of Superparamagnetic Iron Oxide Nanoparticles
  44. Rat brain pro-oxidant effects of peripherally administered 5nm ceria 30 days after exposure
  45. The neurotoxic potential of engineered nanomaterials
  46. Brain microvascular endothelial cell association and distribution of a 5 nm ceria engineered nanomaterial
  47. Influence of surface charge on lysozyme adsorption to ceria nanoparticles
  48. Alteration of hepatic structure and oxidative stress induced by intravenous nanoceria
  49. Distribution, Elimination, and Biopersistence to 90 Days of a Systemically Introduced 30 nm Ceria-Engineered Nanomaterial in Rats
  50. Ceria-engineered nanomaterial distribution in, and clearance from, blood: size matters
  51. Evaluation of 4-hydroxy-6-methyl-3-pyridinecarboxylic acid and 2,6-dimethyl-4-hydroxy-3-pyridinecarboxylic acid as chelating agents for iron and aluminium
  52. Engineered nanomaterials: exposures, hazards, and risk prevention
  53. Brain Distribution and Toxicological Evaluation of a Systemically Delivered Engineered Nanoscale Ceria
  54. Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by aids viruses
  55. Manganese Flux Across the Blood–Brain Barrier
  56. 1,6-Dimethyl-4-hydroxy-3-pyridinecarboxylic acid and 4-hydroxy-2-methyl-3-pyridinecarboxylic acid as new possible chelating agents for iron and aluminium
  57. Biodistribution and oxidative stress effects of a systemically-introduced commercial ceria engineered nanomaterial
  58. Aluminum bioavailability from tea infusion
  59. Manufactured Aluminum Oxide Nanoparticles Decrease Expression of Tight Junction Proteins in Brain Vasculature
  60. Aluminum bioavailability from basic sodium aluminum phosphate, an approved food additive emulsifying agent, incorporated in cheese
  61. The influence of citrate, maltolate and fluoride on the gastrointestinal absorption of aluminum at a drinking water-relevant concentration: A 26Al and 14C study
  62. Interactions between SIRT1 and AP-1 reveal a mechanistic insight into the growth promoting properties of alumina (Al2O3) nanoparticles in mouse skin epithelial cells
  63. Human Health Risk Assessment for Aluminium, Aluminium Oxide, and Aluminium Hydroxide
  64. Evaluation of 1-methyl-3,4-hydroxypyridinecarboxylic acids as possible bidentate chelating agents for iron(III): Metal–ligand solution chemistry
  65. Blood-brain barrier flux of aluminum, manganese, iron and other metals suspected to contribute to metal-induced neurodegeneration
  66. Aluminum bioavailability from the approved food additive leavening agent acidic sodium aluminum phosphate, incorporated into a baked good, is lower than from water
  67. Methyl-Hydroxypyridinecarboxylic Acids as Possible Bidentate Chelating Agents for Aluminium(III): Synthesis and Metal–Ligand Solution Chemistry
  68. The Speciation of Metals in Mammals Influences Their Toxicokinetics and Toxicodynamics and Therefore Human Health Risk Assessment1
  69. The Chemical Species of Aluminum Influences Its Paracellular Flux across and Uptake into Caco-2 Cells, a Model of Gastrointestinal Absorption
  70. Manganese distribution across the blood–brain barrierIV. Evidence for brain influx through store-operated calcium channels
  71. 26Al-containing acidic and basic sodium aluminum phosphate preparation and use in studies of oral aluminum bioavailability from foods utilizing 26Al as an aluminum tracer
  72. Aluminium content of some foods and food products in the USA, with aluminium food additives
  73. Correlation of R2 with total iron concentration in the brains of rhesus monkeys
  74. Complexation of 3,4-hydroxypyridinecarboxylic acids with Iron(III)
  75. Comparison of cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in tumor-bearing mice
  76. Manganese Distribution Across the Blood–Brain Barrier III The Divalent Metal Transporter-1 is not the Major Mechanism Mediating Brain Manganese Uptake
  77. Manganese Distribution Across the Blood–Brain Barrier
  78. Manganese Distribution Across the Blood–Brain Barrier
  79. Evaluation of 3,4-Hydroxypyridinecarboxylic Acids as Possible Bidentate Chelating Agents for Aluminium(III): Synthesis and Metal−Ligand Solution Chemistry
  80. Aluminum chelation principles and recent advances
  81. Aluminum citrate uptake by immortalized brain endothelial cells: implications for its blood–brain barrier transport
  82. Entry, Half-Life, and Desferrioxamine-Accelerated Clearance of Brain Aluminum after a Single 26Al Exposure
  83. Aluminum bioavailability from drinking water is very low and is not appreciably influenced by stomach contents or water hardness
  84. Glomerular lesions in male rabbits treated with aluminium lactate: with special reference to microaneurysm formation
  85. The Hexadentate Hydroxypyridinonate TREN‐(Me‐3,2‐HOPO) is a More Orally Active Iron Chelator Than Its Bidentate Analogue
  86. The distribution of aluminum into and out of the brain
  87. Postmortem elevation in extracellular glutamate in the rat hippocampus when brain temperature is maintained at physiological levels: implications for the use of human brain autopsy tissues
  88. Aluminum and phosphorus separation: application to preparation of target from brain tissue for 26Al determination by accelerator mass spectrometry
  89. Aluminum transport out of brain extracellular fluid is proton dependent and inhibited by mersalyl acid, suggesting mediation by the monocarboxylate transporter (MCT1)
  90. An Aluminum-Induced Increase in GFAP Is Attenuated by Some Chelators
  91. Aluminum citrate is transported from brain into blood via the monocar☐ylic acid transporter located at the blood-brain barrier
  92. Intraneuronal aluminum potentiates iron-induced oxidative stress in cultured rat hippocampal neurons
  93. Hippocampal Acetylcholine Increases During Eyeblink Conditioning in the Rabbit
  94. PREVENTION AND TREATMENT OF ALUMINUM TOXICITY INCLUDING CHELATION THERAPY: STATUS AND RESEARCH NEEDS
  95. Aluminum chelation by 3-hydroxypyridin-4-ones in the rat demonstrated by microdialysis
  96. The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2 dimethyl-, 1,2 diethyl-, and 1-[ethan-1′ ol]-2-methyl-3-hydroxypyridin-4-one in the rat
  97. Aluminum Facilitation of Iron-Mediated Lipid Peroxidation Is Dependent on Substrate, pH, and Aluminum and Iron Concentrations
  98. HPLC Quantitation of a Very Hydrophilic 3-Hydroxypyridin-4-one Chelator Using a Simple Separation Procedure and the Baseline File Subtraction Method
  99. Delayed elevation of platelet activating factor in ischemic hippocampus
  100. Selective adherence of a sucralfate—tetracycline complex to gastric ulcers: Implications for the treatment ofHelicobacter pylori
  101. Evidence for energy-dependent transport of aluminum out of brain extracellular fluid
  102. A phase I trial of 5-day continuous infusion cisplatin and interferon ?
  103. Studies of aluminum neurobehavioral toxicity in the intact mammal
  104. Pharmacokinetics of aluminum 3-hydroxypyridin-4-one complexes: implications for aluminum redistribution subsequent to chelation therapy
  105. Application of electron energy loss spectroscopy and electron spectroscopic imaging to aluminum development in biological tissue
  106. Application of electron energy loss spectroscopy and electron spectroscopic imaging to aluminum development in biological tissue
  107. Application of electron energy loss spectroscopy and electron spectroscopic imaging to aluminum determination in biological tissue
  108. 4-trimethylammonium antipyrine: A quaternary ammonium nonradionuclide marker for blood-brain barrier integrity during in vivo microdialysis
  109. Antipyrine as a dialyzable reference to correct differences in efficiency among and within sampling devices during in vivo microdialysis
  110. Dissimilar Aluminum and Gallium Permeation of the Blood-Brain Barrier Demonstrated by In Vivo Microdialysis
  111. Aluminum mobilization by desferrioxamine assessed by microdialysis of the blood, liver and brain☆☆☆
  112. Aluminum distribution into brain and liver of rats and rabbits following intravenous aluminum lactate or citrate: A microdialysis study*1, *2
  113. Renal accumulation and urinary excretion of cisplatin in diabetic rats
  114. Effect of Dietary Aluminum Sulfate on Calcium and Phosphorus Metabolism of Broiler Chicks
  115. Relationship of Dietary Aluminum, Phosphorus, and Calcium to Phosphorus and Calcium Metabolism and Growth Performance of Broiler Chicks
  116. Reduced intestinal calcium and dietary calcium intake, increased aluminum absorption, and tissue concentration in the rat
  117. The influence of dietary calcium reduction on aluminum absorption and kinetics in the rabbit
  118. Elevated aluminum persists in serum and tissues of rabbits after a six-hour infusion
  119. Aluminum produces age related behavioral toxicity in the rabbit
  120. Benefit Vs. Risk of Oral Aluminum Forms: Antacid and Phosphate Binding Vs. Absorption
  121. Aluminum and Alzheimer's Disease: Should We Worry?
  122. Influence of renal impairment, chemical form, and serum protein binding on intravenous and oral aluminum kinetics in the rabbit
  123. Assessment of potential aluminum chelators in an octanol/aqueous system and in the aluminum-loaded rabbit
  124. Toxicity of aluminum exposure to the neonatal and immature rabbit*1, *2
  125. Toxicity of Aluminum Exposure to the Neonatal and Immature Rabbit
  126. Toxicity of gestational aluminum exposure to the maternal rabbit and offspring
  127. Aluminum bioavailability and disposition in adult and immature rabbits
  128. Toxicity of aluminum exposure during lactation to the maternal and suckling rabbit*1
  129. Persistent aluminum accumulation after prolonged systemic aluminum exposure
  130. A safe method to acid digest small samples of biological tissues for graphite furnace atomic absorption analysis of aluminum
  131. Evaluation of Factors Influencing the Patterns of Use of Drug and Poison Information Resources
  132. Acute toxicity of latex microspheres
  133. Effects of plant ingestion in rats determined by the conditioned taste aversion procedure
  134. The Impact of Video Technology on the Use of Drug Information Resources
  135. The Influence of Human and Data Retrieval Resources on the Patterns of Use of Drug Information
  136. Abuse and Pulmonary Complications of Injecting Pentazocine and Tripelennamine Tablets
  137. The influence of neuroleptics on amphetamine metabolism in the rat and guinea-pig*
  138. A comparison of four toxicology resources in respect to rates of retrieval and time required
  139. Amphetamine-type reinforcement by dopaminergic agonists in the rat
  140. Concurrent intracranial self-stimulation and amphetamine self-administration in rats
  141. Past, Present and Future of Drug Information Centers as Catalysts for the Utilization of Drug Therapy Information
  142. Drug Information Communication via Television
  143. Both positive reinforcement and conditioned aversion from amphetamine and from apomorphine in rats
  144. Extinction responding following amphetamine self-administration: Determination of reinforcement magnitude
  145. Attenuation of intravenous amphetamine reinforcement by central dopamine blockade in rats
  146. Drug level of d- and l-amphetamine during intravenous self-administration
  147. Aluminum